Boston Scientific to begin trial of Precision neurostimulator to treat migraine headaches

By Angela McDaniels

Seattle, Nov. 10 - Boston Scientific Corp. said it has received approval from the U.S. Food and Drug Administration to begin a clinical trial to evaluate the safety and efficacy of occipital nerve stimulation as a treatment for refractory migraine headaches in patients who do not respond to other therapies.

The study will use Boston Scientific's Precision neurostimulator and involve about 150 patients at up to 15 sites in the United States.

The device will be used to deliver electrical impulses to the occipital nerves located just under the skin at the back of the neck.

Precision is approved by the FDA for spinal cord stimulation to treat chronic pain in the limbs, trunk and back, the company said, and has been used in the treatment of more than 2,000 patients suffering from chronic pain.

Boston Scientific is based in Natick, Mass., and develops medical devices.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.